6[6]Davis KL, Kahn RS, Ko G, et al.Dopamine in schizophrenia: a review and reconceptualization[J].Am J Psychiatry, 1991,148(11): 1474-1486.
7[7]Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia[J].Am J Psychiatry,1991,148(10): 1301-1308.
8[8]Pickard BA.Clinical and biochemical effects of neuroleptic treatment:Implications for the pathophysiology of schizophrenia[A]. In:Schulz SC,Tamminga CA. Schizophrenia:Scientific Progress[C]. Oxford:Oxford University Press,1989.285.
3Kazutoyo I, Shin I, Akinori U, et al. Phase I study of perospirone HCl(SM-9018). Clinical Report, 1997, 31(6) : 188
4Mario N. Biotransformation of post-clozapine antipsychotics pharmacological implications. Clin Pharmacokinet, 2000, 38(5) : 393
5Takahashi Y, Kusumi I, Ishikane T, et al. In vivo occupation of dopa mine D1, D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm,1998, 105(2-3) : 181
6Tanaka H, Ohno Y, Nakamure M. Localization and pharmacological characterization of [3H] perospirone-binding sites in rat brain.Gen Pharmcal, 1998, 31(1) : 159
7Ishibashi T, Tagashira R, Nakamure M, et al. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on fos protein expression in the rat forebrain. Pharmacol biochem Behav, 1999,63(4) : 535
8Ohno Y, Ishida T, Okuda K, et al. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol, 1997, 49 :213
9Sakamoto H, Matsumoto K, Ohno Y, et al. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent. Pharmacol Biochem Behav,1998, 60(4) : 873
10Ishida T, Okuda K, Ohno Y, et al. Evaluation of perospirone, a novel serotonin-2 an dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced frezzing behavior model in rats. Jph Phamacol, 1996, 72(2) : 119
